Pyxis Oncology Files Prospectus For Offering 39.2M Common Shares On Behalf Of Selling Shareholders
https://www.sec.gov/Archives/edgar/data/1782223/000119312526359246/pyxs-20260820.htm
Stocks · News reference
Wells Fargo Initiates Coverage On Pyxis Oncology with Overweight Rating, Announces Price Target of $12
Wells Fargo analyst Derek Archila initiates coverage on Pyxis Oncology (NASDAQ:PYXS) with a Overweight rating and announces Price Target of $12.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $7 price target.
8-K filing — Pyxis Oncology, Inc. (PYXS)
Filed: 2026-08-13 AccNo: 0001193125-26-347911 Size: 492 KB Item 2.02: Results of Operations and Financial Condition
Pyxis Oncology Q2 EPS $(0.40) Misses $(0.35) Estimate
Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.35) by 14.29 percent. This is a 33.33 percent decrease over losses of $(0.30) per share from